On Monday, 28 September 2025, a State of the Art Session was held at the European Respiratory Society (ERS) Annual Congress 2025 titled: “Pulmonary Hypertension associated with lung diseases: the most burning questions.” The session was chaired by Prof. Dr. Olivier Sitbon, Prof. Dr. David Montani, and Dr. Nesrin Ocal. Leading experts shared the latest […]
The phase 3 HYPERION trial on sotatercept enrolled 320 adults with newly diagnosed pulmonary arterial hypertension (within 1 year of diagnosis) at intermediate or high risk who were already on double or triple background therapy. Patients were randomized to receive add-on subcutaneous sotatercept or placebo every 21 days. The trial stopped early due to compelling
Despite historical use, the role of anticoagulant therapy in the management of pulmonary arterial hypertension (PAH) remains uncertain, as existing epidemiologic studies have produced conflicting results. The goal of a study whose findings were published in the Journal of the American College of Cardiology on September 30, 2025, was to examine the association between anticoagulant
Pulmonary arterial hypertension (PAH) happens when the blood vessels in the lungs become too narrow and stiff. This raises pressure in the lungs and puts strain on the heart. In a collaborative study, scientists from Inserm and Université Paris-Saclay in France, together with researchers from the Institute for Lung Health (ILH) in Germany, discovered
What is pulmonary arterial hypertension and why does risk assessment matter? Pulmonary arterial hypertension is a rare, serious disease where the blood vessels in thelungs become too narrow. This makes the right side of the heart work harder, which overtime can lead to heart failure. Because it can progress quickly, doctors use risk assessment (sometimes
The key findings from the Pulmonary Hypertension Global Patient Survey (PHGPS) adult cohort of 3,329 patients have been published in the ERJ Open Research 2025, highlighting the achievements, shortcomings & regional disparities of clinical care & research globally. The Pulmonary Hypertension Global Patient Survey represents the most extensive survey of its type in the pulmonary
Ralinepag is a novel prostacyclin receptor agonist. It is designed to mimic prostacyclin, a molecule that reduces blood pressure by relaxing blood vessels. It is a once-daily oral formulation. United Therapeutics has announced the completion of enrollment for its ADVANCE OUTCOMES, a Phase 3 clinical trial testing ralinepag for pulmonary arterial hypertension (PAH). The study
Researchers used computer modeling to compare immediate versus delayed (2-year) treatment with sotatercept, a new pulmonary arterial hypertension medication, to predict lifetime outcomes. Study Method: Building on the findings of the phase 3 STELLAR trial on sotatercept the authors of the study refer to a population health model which was recently published assessing the long-term
Pulmonary arterial hypertension has a higher prevalence in women than men, yet notable sex-based differences influence disease presentation, treatment response, and outcomes. Based on data from major pulmonary arterial hypertension clinical trials the authors of a recent study published in Therapeutic Advances in Respiratory Disease have found that: These sex-based differences, say the authors, highlight
Existing treatments pulmonary arterial hypertension (PAH) widen blood vessels, can help relieve symptoms and extend life, but cannot cure the disease or repair the damaged vessels. The field is now moving toward treatments that could actually modify the underlying disease process, based on promising laboratory research that’s being tested in patients. Two important breakthroughs include
Louise Bouman, Chair of Stichting Pulmonale Hypertensie (PHA Netherlands) and Board Member of the Alliance for Pulmonary Hypertension is just back from Amsterdam where she attended the Pulmonary Vascular Institute (PVRI) Symposium on Drug Discovery and Development taking place on June 16-17. “I recently had the opportunity to attend an inspiring symposium organized by the
This study focused on some of the sickest pulmonary arterial hypertension patients – those with advanced disease who were already on the best available treatments but still faced a high risk of dying within the next year. For these patients, doctors have traditionally had limited options. Researchers enrolled 172 high-risk patients who were already receiving
TPIP is a new version of an existing pulmonary arterial hypertension medication called treprostinil. It is designed as a “prodrug” – meaning it becomes active only after the body processes it. The key advantage is that TPIP can be taken as a dry powder in a capsule-based inhaler, once daily. In a 102-patient phase 2b
Patients with pulmonary hypertension are classified according to clinical criteria to inform treatment decisions. Knowledge of the molecular drivers of pulmonary hypertension might better inform treatment choice, say researchers involved in a study published in May in the American Journal of Respiratory and Critical Care Medicine. The researchers studied blood samples from 470 people who
Selexipag is an oral selective IP prostacyclin receptor agonist. This study, presented during an oral session at the International Society for Heart and Lung Transplant (ISHLT) congress on April 29, 2025, provides the longest follow-up data available for any pulmonary arterial hypertension therapy, tracking 574 patients originally randomized to selexipag in the GRIPHON trial, with
The EXPOSURE study compared survival rates between pulmonary arterial hypertension (PAH) patients newly treated with selexipag versus other pulmonary arterial hypertension-specific therapies. Survival analyses in EXPOSURE suggest a reduced risk of mortality among the cohort of patients newly initiated on selexipag compared with the modelled cohort newly initiated with other pulmonary arterial hypertension-specific therapies. Further
Prostacyclin therapies, for pulmonary arterial hypertension, especially the parenteral ones, are associated with treatment burden, risks, and high costs. Authors Karen M Olsson, Jan Fuge, Da-Hee Park,Jan C. Kamp, and Marius M. Hoeper have investigated this possibility in a small series of pulmonary arterial hypertension patients treated with sotatercept. Withdrawal of selexipag was found safe,
Pulmonary arterial hypertension (PAH) represents a significant economic burden on society, as revealed by a comprehensive Swedish study published on Pulmonary Circulation on April 17, 2025, examining the societal costs associated with this condition. The research tracked patients across various pulmonary arterial hypertension subgroups—idiopathic/hereditary pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue disease,
Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach targeting the sympathetic nervous system’s role in pulmonary hypertension, reveal the findings of a metanalysis reviewing 14 studies, involving 372 patients. Pulmonary Artery Denervation improved several key hemodynamic parameters and clinical outcomes. The meta-analysis was published in the May 2025 edition of the International Journal
The findings of a prospective study on 93 patients (66% women, 75% PAH, 25% CTEPH, 57±17 years), all on pulmonary hypertension-targeted oral medication, between 2013 and 2023, were recently published in the British Medical Journal Open Respiratory Research. These reveal that mean MPR (Medication Possession Ratio) and self-reported adherence were overall high, with 78% of patients
